Interview with Chen Chun Lin, Co-Chairman, Medicilon/MPI Preclinical Research…
You completed your higher education in the US and worked there for a period afterwards; what caused you to move…
Address: 585 Chuanda Road, Pudong New AreaShanghai, 201200,China
Tel: +86 21 31268381
Web: http://www.medicilon-mpi.com/
As a newly formed joint venture located in China, Medicilon/MPI Preclinical Research Shanghai provides a portfolio of preclinical discovery and development services to pharmaceutical and biotechnology companies.
Medicilon/MPI Preclinical Research Shanghai has brought together the best of its parent companies, Shanghai Medicilon and MPI Research, to assure top quality, on-time GLP and non-GLP studies.
toxicology services
You completed your higher education in the US and worked there for a period afterwards; what caused you to move…
In March 2018, German pharma player Boehringer Ingelheim (BI)‘s Consanas Rehabilitation and the Shanghai…
Dr Haijun Dong, recently appointed CEO of BioDuro-Sundia, shares his priorities for the newly merged entity, one of…
Kevin Rufang Huang, president and founder of the Chinese Organization for Rare Disorders (CORD), outlines the…
The latest from Chinese pharma, including a new deal between AstraZeneca and Junshi Biosciences; Innoforce and…
One of the largest domestic pharma companies in China (ranking number one from 2014 to 2019), Yangtze River…
HiFiBiO Therapeutics cofounder, CEO and CSO Dr Liang Schweizer fits the profile of a Chinese biotech CEO to a T:…
Writing in the February edition of DIA’s Global Forum magazine, Xu Wang of Novo Nordisk Pharma China and Xiaoxi…
Dr Liang Schweizer introduces immunotherapy-focused biotech HiFiBiO Therapeutics, the main advantages of the…
Eric Bouteiller examines the most recent update to China’s National Reimbursement Drug List, the positive impact…
Since China first announced its ground-breaking volume-based procurement (VBP) pilot program to reduce drug…
2020 has been eventful – perhaps the understatement of the year – but despite the novel coronavirus being…
Following the recent news of Remegen’s massive USD 515 million IPO in November 2020, we bring you profiles of…